C
0.690
-0.01 (-1.63%)
| Penutupan Terdahulu | 0.702 |
| Buka | 0.680 |
| Jumlah Dagangan | 305,664 |
| Purata Dagangan (3B) | 1,318,154 |
| Modal Pasaran | 49,378,312 |
| Harga / Buku (P/B) | 2.95 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -0.380 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.66% |
| Nisbah Semasa (MRQ) | 0.360 |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -1.26 M |
| Pulangan Atas Aset (ROA TTM) | -22.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -93.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Citius Oncology, Inc. | Bercampur | - |
AISkor Stockmoo
0.1
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.13 |
|
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| % Dimiliki oleh Orang Dalam | 95.07% |
| % Dimiliki oleh Institusi | 0.76% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 17 Jun 2025 | Pengumuman | Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025 |
| 10 Jun 2025 | Pengumuman | Citius Pharmaceuticals Announces a Registered Direct Offering of Up To $15.8 Million Priced At-The-Market Under Nasdaq Rules |
| 09 Jun 2025 | Pengumuman | Citius Oncology Enters into Distribution Services Agreement with Cardinal Health |
| 14 May 2025 | Pengumuman | Citius Oncology, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update |
| 14 May 2025 | Pengumuman | Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update |
| 05 May 2025 | Pengumuman | Citius Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |
| 01 Apr 2025 | Pengumuman | Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |